Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$127.00 USD

127.00
7,125,347

+0.12 (0.09%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $127.02 +0.02 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 11% (224 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sweta Killa headshot

Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?

by Sweta Killa

While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.

Kinjel Shah headshot

4 Large Drug Stocks to Hold on to Amid Industry Challenges

by Kinjel Shah

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.

Ahan Chakraborty headshot

What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?

by Ahan Chakraborty

Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PJP

How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?

by Zacks Equity Research

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.

Exploring Analyst Estimates for Merck (MRK) Q1 Earnings, Beyond Revenue and EPS

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.

Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline

by Zacks Equity Research

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck (MRK) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck (MRK) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

In the most recent trading session, Merck (MRK) closed at $125.37, indicating a +0.25% shift from the previous trading day.

Sheraz Mian headshot

Top Analyst Reports for Microsoft, Novo Nordisk & United Parcel

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Novo Nordisk A/S (NVO) and United Parcel Service, Inc. (UPS).

Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

In the closing of the recent trading day, Merck (MRK) stood at $126.15, denoting a -0.47% change from the preceding trading day.

Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study

by Zacks Equity Research

Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.

Company News for Apr 10, 2024

by Zacks Equity Research

Companies in The News Are: MRNA, MRK, COIN, BN, NEOG

Corcept (CORT) Completes Enrollment in Ovarian Cancer Study

by Zacks Equity Research

The phase III ROSELLA study is evaluating Corcept's (CORT) relacorilant plus nab-paclitaxel for treating recurrent, platinum-resistant ovarian cancer. Enrollment in the study has been completed.

Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)

by Zacks Equity Research

Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.

Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

by Zacks Equity Research

Merck (MRK) concluded the recent trading session at $127.99, signifying a +0.26% move from its prior day's close.

eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails

by Zacks Equity Research

eFFECTOR Therapeutics (EFTR) plunges on disappointing top-line results from the primary analysis of its mid-stage NSCLC study of tomivosertib, following the abandonment of the developmental program.

Kinjel Shah headshot

Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III

by Kinjel Shah

FDA approves AstraZeneca's (AZN) Voydeya (danicopan) in the United States as add on therapy to its other C5 inhibitors. Merck (MRK) begins a phase III study on its oral KRAS G12C inhibitor candidate.

Merck (MRK) Begins Phase III NSCLC Study on KRAS Candidate

by Zacks Equity Research

Merck's (MRK) phase III study will evaluate KRAS G12C inhibitor candidate MK-1084 for first-line treatment of certain patients with metastatic NSCLC.

Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA

by Zacks Equity Research

Kintara (KTRA) inks a definitive merger agreement with TuHURA for an all-stock transaction. It is expected to close in the third quarter of 2024. The stock surges 63.4%.

Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up

by Zacks Equity Research

Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.

Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug

by Zacks Equity Research

Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Merck (MRK) reachead $129.90 at the closing of the latest trading day, reflecting a -0.35% change compared to its last close.

Why Merck (MRK) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Merck (MRK) Rises Higher Than Market: Key Facts

by Zacks Equity Research

Merck (MRK) reachead $131.95 at the closing of the latest trading day, reflecting a +0.15% change compared to its last close.